BR112012004281A2 - uso de metformina tratamento e prevenção de câncer - Google Patents

uso de metformina tratamento e prevenção de câncer

Info

Publication number
BR112012004281A2
BR112012004281A2 BR112012004281A BR112012004281A BR112012004281A2 BR 112012004281 A2 BR112012004281 A2 BR 112012004281A2 BR 112012004281 A BR112012004281 A BR 112012004281A BR 112012004281 A BR112012004281 A BR 112012004281A BR 112012004281 A2 BR112012004281 A2 BR 112012004281A2
Authority
BR
Brazil
Prior art keywords
prevention
cancer treatment
use cancer
metformin use
metformin
Prior art date
Application number
BR112012004281A
Other languages
English (en)
Inventor
Dimitrios Iliopoulos
Heather Hirsch
Kevin Struhl
Original Assignee
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College filed Critical Harvard College
Publication of BR112012004281A2 publication Critical patent/BR112012004281A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112012004281A 2009-08-25 2010-08-25 uso de metformina tratamento e prevenção de câncer BR112012004281A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23677809P 2009-08-25 2009-08-25
PCT/US2010/046616 WO2011031474A2 (en) 2009-08-25 2010-08-25 Use of metformin in cancer treatment and prevention

Publications (1)

Publication Number Publication Date
BR112012004281A2 true BR112012004281A2 (pt) 2016-03-08

Family

ID=43733025

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012004281A BR112012004281A2 (pt) 2009-08-25 2010-08-25 uso de metformina tratamento e prevenção de câncer

Country Status (14)

Country Link
US (1) US20120220664A1 (pt)
EP (1) EP2470170A4 (pt)
JP (1) JP2013503171A (pt)
KR (1) KR20120080579A (pt)
CN (1) CN102596192A (pt)
AU (1) AU2010292599A1 (pt)
BR (1) BR112012004281A2 (pt)
CA (1) CA2772120A1 (pt)
IL (1) IL218287A0 (pt)
IN (1) IN2012DN01964A (pt)
MX (1) MX2012002337A (pt)
SG (1) SG178556A1 (pt)
WO (1) WO2011031474A2 (pt)
ZA (1) ZA201201434B (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011084523A2 (en) * 2009-12-15 2011-07-14 The Salk Institute For Biological Studies Ulk1 compositions, inhibitors, screening and methods of use
SG191048A1 (en) * 2010-12-06 2013-07-31 Cure Cancer Worldwide Corp Methods of metabolic targeting cancer cells using che mo- and immunotherapy for treating cancer
WO2012171015A2 (en) * 2011-06-10 2012-12-13 Translational Genomics Research Institute Therapeutic combination for cancer treatment
CN102327256B (zh) * 2011-09-22 2014-01-29 上海交通大学医学院附属瑞金医院 二甲双胍在制备治疗淋巴瘤疾病药物中的应用
WO2013086002A1 (en) * 2011-12-05 2013-06-13 Cellworks Research India Private Limited Compositions, process of preparation of said compositions and method of treating cancer
CA3159085A1 (en) 2013-01-14 2014-07-17 Clinics Operations Limited Combination cancer therapeutics and uses thereof
CN112023054A (zh) 2013-04-12 2020-12-04 内德生物系统有限公司 癌症的治疗
JP6242071B2 (ja) * 2013-04-23 2017-12-06 国立大学法人 岡山大学 免疫疲弊ｃｄ８＋ｔ細胞の機能改善薬、がん治療薬及びメタボリック症候群の予防または治療薬
AU2014269401A1 (en) 2013-05-24 2016-01-21 Otsuka Pharmaceutical Co., Ltd. Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer
US10166246B2 (en) 2014-05-27 2019-01-01 City Of Hope TGR5 agonist complexes for treating diabetes and cancer
CN107205968B (zh) * 2014-08-14 2021-08-20 威斯康星州医药大学股份有限公司 修饰的线粒体-二甲双胍化合物及其合成和使用方法
RU2731098C2 (ru) * 2014-08-19 2020-08-28 Нэшнл Юниверсити Корпорейшн Окаяма Юниверсити Способ улучшения функции иммунных клеток и оценки мультифункциональности иммунных клеток
WO2016026933A1 (en) * 2014-08-21 2016-02-25 Centre National De La Recherche Scientifique - Cnrs - Adjuvant or neoadjuvant therapy for sensitizing cancer stem cells to chemotherapy
JP7189020B2 (ja) * 2016-02-16 2022-12-13 エイジェンシー・フォー・サイエンス，テクノロジー・アンド・リサーチ 癌のエピジェネティックプロファイリング
US10813909B2 (en) 2016-05-19 2020-10-27 The Regents Of The University Of California Triple drug combination (metformin, simvastatin, digoxin) for targeted treatment of pancreatic cancer
CN106727468A (zh) * 2017-04-01 2017-05-31 四川大学 二甲双胍及联合二甲双胍和长春新碱在制备治疗白血病药物中的应用及药物组合物
EP3612177A4 (en) 2017-04-21 2021-01-13 Lunella Biotech, Inc. TARGETING HYPOXIC CARCINOUS STEM CELLS (SCC) USING DOXYCYCLINE: IMPLICATIONS FOR IMPROVING ANTI-ANGIOGENIC THERAPY
US11197872B2 (en) 2017-04-21 2021-12-14 Lunella Biotech, Inc. Vitamin C and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (CSCs)
CA3063450A1 (en) 2017-05-19 2018-11-22 Lunella Biotech, Inc. Companion diagnostics for mitochondrial inhibitors
KR20200010343A (ko) 2017-05-19 2020-01-30 루넬라 바이오테크 인코포레이티드 안티미토신: 암 줄기 세포를 근절하기 위한 미토콘드리아 생물발생의 표적화 억제제
WO2019183003A1 (en) * 2018-03-18 2019-09-26 The University Of North Carolina At Chapel Hill Methods and assays for endometrial diseases
CN111617255B (zh) * 2019-02-28 2023-08-18 北京强新生物科技有限公司 用于治疗中枢神经系统紊乱的组合疗法
KR102312100B1 (ko) * 2020-06-05 2021-10-14 (주)프론트바이오 항바이러스제 및 항우울제를 유효성분으로 함유하는 암 예방 또는 치료용 약학적 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006031931A2 (en) * 2004-09-15 2006-03-23 The President And Fellows Of Harvard College Reducing er stress in the treatment of obesity and diabetes
US7465804B2 (en) * 2005-05-20 2008-12-16 Amgen Inc. Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders
DE102006026026A1 (de) * 2006-06-01 2007-12-06 Grünenthal GmbH Arzneimittel
WO2008097861A2 (en) * 2007-02-02 2008-08-14 Braincells, Inc. MODULATION OF NEUROGENESIS WITH BIGUANIDES AND GSK3-ß AGENTS
WO2008110491A2 (en) * 2007-03-09 2008-09-18 University Of Basel Chemotherapy of neoplastic diseases using combinations of rapamycin and compounds modulating mtor pathway alone or in combination with heat
WO2009101199A2 (en) * 2008-02-15 2009-08-20 Bodo Melnik Treatment of acne vulgaris; rosacea and rhinophym

Also Published As

Publication number Publication date
WO2011031474A3 (en) 2011-06-16
JP2013503171A (ja) 2013-01-31
IN2012DN01964A (pt) 2015-08-21
AU2010292599A1 (en) 2012-03-15
EP2470170A4 (en) 2013-01-02
ZA201201434B (en) 2013-05-29
CA2772120A1 (en) 2011-03-17
EP2470170A2 (en) 2012-07-04
MX2012002337A (es) 2012-06-25
WO2011031474A2 (en) 2011-03-17
IL218287A0 (en) 2012-04-30
CN102596192A (zh) 2012-07-18
US20120220664A1 (en) 2012-08-30
SG178556A1 (en) 2012-03-29
KR20120080579A (ko) 2012-07-17

Similar Documents

Publication Publication Date Title
BR112012004281A2 (pt) uso de metformina tratamento e prevenção de câncer
BR112012005594A2 (pt) tratamento de câncer
BRPI1016199A2 (pt) cobertura de ferimento e kit de tratamento de ferimentos.
BRPI1012533A2 (pt) composto de piradazinona e uso do mesmo
BRPI1007972A2 (pt) composições de combinação e métodos para o tratamento de câncer
BR112012002349A2 (pt) composto,e, uso do mesmo
BRPI1008566A2 (pt) métodos e composições para o diagnóstico e tratamento de câncer
BRPI1013698A2 (pt) métodos para tratamento com o uso de terapia de combinação
BRPI1011916A2 (pt) uso de uma combinação de filtro uv, e, preparação cosmética.
BRPI0919238A2 (pt) métodos e composições para o tratamento de câncer
BR112012001260A2 (pt) conjugados de epsilon-polilisina e o emprego dos mesmos
BRPI1007494A2 (pt) composto e uso do mesmo
BRPI1008564A2 (pt) métodos e composições para o dignóstico e tratamento de câncer
BR112012002269A2 (pt) implemento para tratar superfície
SMT201700056B (it) Fosfaplatine e relativo utilizzo per il trattamento di cancro
BR112012001797A2 (pt) composto bicíclico e uso do mesmo para propósitos médicos
BRPI0919759A2 (pt) polipeptídeos para tratamento e prevenção de adesões
BRPI1007995A2 (pt) orto-aminoamidas para o tratamento de cãncer.
DK2235002T3 (da) 4-pyridinonforbindelser og anvendelse heraf til behandling af cancer
BRPI0811870A2 (pt) Tratamento e prevenção de influenza
BRPI0922884A2 (pt) compostos para tratamento de câncer
DK2173831T3 (da) Brøndbehandling
EP2457092A4 (en) CANCER BIOMARKERS AND THEIR USE
BRPI0812932A2 (pt) Composições e métodos de tratar câncer
BRPI1011036A2 (pt) uso

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]